Melanoma antigens and their use in diagnostic and therapeutic methods
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsYutaka Kawakami, Steven A. Rosenberg
Life of this patent
Estimating the term…
Abstract
The present invention provides an isolated or purified immunogenic peptide comprising 8-15 contiguous amino acids of gp100 (SEQ ID NO: 121) and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use. The invention further provides immunogenic peptides derived from gp100 which have been modified to enhance their immunogenicity and related nucleic acids, expression vectors, host cells, populations of cells, and methods of use.
Claims26
An isolated or purified nucleotide sequence encoding an immunogenic peptide consisting of 8-15 contiguous amino acids of gp100 (SEQ ID NO:
- 121).
A nucleotide sequence encoding an immunogenic peptide consisting of 8-15 contiguous amino acids of gp100 (SEQ ID NO:
- 121), wherein the peptide encoded by the nucleotide sequence includes at least one amino acid modification in the 8-15 contiguous amino acids of SEQ ID NO:
- 121, wherein the immunogenic peptide reacts with T-lymphocytes.
Dependencies are inferred from the claim text.